If you have been reading about Peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability depends heavily on physical state. Lyophilized powder held dry, cold and dark retains its content over long periods, whereas dissolved peptide begins to change within days at room temperature. The most cited degradation route is oxidation of the methionine residue, which converts the peptide to a sulfoxide form that elutes differently on chromatography. Hydrolysis of amide bonds and adsorption onto container walls contribute smaller losses. Buffers that exclude oxygen from the headspace slow the oxidation pathway, but no single condition prevents all change indefinitely.
Practical handling follows from those properties. Bulk material is best divided into single-use portions soon after receipt, because each thaw exposes the whole container to moisture and temperature cycling. Vials should be allowed to reach room temperature before opening to prevent condensation on the powder. Low-binding plasticware reduces loss of dilute solutions, and sterile filtration is used when a preparation must remain free of microbial growth. Records of batch number, reconstitution date and storage history are what allow a later analytical result to be interpreted meaningfully.
Identity and purity of Semax are established mainly by reversed-phase high-performance liquid chromatography coupled with mass spectrometry. The chromatographic trace gives a purity estimate as a percentage of total peak area, while electrospray or matrix-assisted laser desorption ionization confirms the molecular mass against the calculated value. Amino acid analysis and sequence-specific fragmentation provide further confirmation when a supplier's chain of custody is unclear. Vendors frequently quote a purity figure without stating the detection wavelength or the integration method, which limits how far one number can be compared with another.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | ≥ 95 % of peak area by HPLC | Some suppliers quote 98 % or higher |
| Identity confirmation | Mass spectrometry (electrospray or MALDI) | Observed mass is compared with the calculated mass |
| Common analytical method | Reversed-phase HPLC on a C18 column | Acetonitrile and water gradients with trifluoroacetic acid |
| Primary degradation route | Oxidation of the methionine residue | Yields a sulfoxide that separates cleanly on chromatography |
| Storage of dissolved material | Aliquoted and frozen at −20 °C or below | Single-use aliquots avoid repeated temperature cycling |
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
There are four basic types of animal tissues: muscle tissue, nervous tissue, connective tissue, and epithelial tissue. All animal tissues are considered to be subtypes of these four principal tissue types (for example, blood is classified as connective tissue, since the blood cells are suspended in an extracellular matrix, the plasma).
Einsteinium is produced in minute quantities by bombarding lighter actinides with neutrons in dedicated high-flux nuclear reactors. The world's major irradiation sources are the 85-megawatt High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory (ORNL), Tennessee, U.S., and the SM-2 loop reactor at the Research Institute of Atomic Reactors (NIIAR) in Dimitrovgrad, Russia, which are both dedicated to the production of transcurium (Z>96) elements. These facilities have similar power and flux levels, and are expected to have comparable production capacities for transcurium elements, though the quantities produced at NIIAR are not widely reported. In a "typical processing campaign" at ORNL, tens of grams of curium are irradiated to produce decigram quantities of californium, milligrams of berkelium (249Bk) and einsteinium and picograms of fermium. The first microscopic sample of 253Es weighing about 10pr nanograms was prepared in 1961 at HFIR. A special magnetic balance was designed to estimate its weight. Larger batches were produced later starting from several kilograms of plutonium with the einsteinium yields (mostly 253Es) of 0.48 milligram in 1967–1970, 3.2 milligrams in 1971–1973, followed by steady production of about 3 milligrams per year between 1974 and 1978. These quantities however refer to the integral amount in the target right after irradiation. Subsequent separation procedures reduced the amount of isotopically pure einsteinium roughly tenfold.
Preotact contains recombinant human parathyroid hormone which is identical to the full-length native 84-amino acid polypeptide. Physiological actions of parathyroid hormone include stimulation of bone formation by direct effects on bone forming cells (osteoblasts) indirectly increasing the intestinal absorption of calcium and increasing the tubular reabsorption of calcium and excretion of phosphate by the kidney.
Sources: en.wikipedia.org
The high degree of interconnectivity in monoliths confers an advantage seen in the low backpressures and readily achievable high flow rates. Monoliths are ideally suited for large molecules; although the purification of larger molecules can be very time-consuming. As mentioned previously, particle sizes are decreasing in an attempt to achieve higher resolution and faster separations, which led to higher backpressures. When the smaller particle sizes are used to separate biomolecules, backpressures increase further because of the large molecule size. In monoliths, where backpressures are low and channel sizes are large, small molecule separations are less efficient. This is demonstrated by the dynamic binding capacities, a measure of how much sample can bind to the surface of the stationary phase. Dynamic binding capacities of monoliths for large molecules can be an order of ten times greater than that for particulate packings. Monoliths exhibit no shear forces or eddying effects. High interconnectivity of the mesopores allows for multiple avenues of convective flow through the column. Mass transport of solutes through the column is relatively unaffected by flow rate. This is completely at odds to traditional particulate packings, whereby eddy effects and shear forces contribute greatly to the loss of resolution and capacity, as seen in the vanDeemter curve. Monoliths can, however, suffer from a different flow disadvantage: wall effects. Silica monoliths, especially, have a tendency to pull away from the sides of their column encasing.
=== 1991 === 11 August After Desert Storm, the technology deployed in the Gulf War, and whether any lessons were learned - featured Major General Sir Peter de la Billière, Commander of the British Forces in the Gulf; a 66-foot-long F117 at King Khalid Air Base at Khamis Mushait on 16 January 1991 - the aircraft had no radar, but had the radar signature of a small bird; F117 pilot Major Greg Feest; Air Vice-Marshal Bill Written, the air commander of British Forces Middle East from November 1990; Colonel John A.
A laser microprobe mass spectrometer (LMMS), also laser microprobe mass analyzer (LAMMA), laser ionization mass spectrometer (LIMS), or laser ionization mass analyzer (LIMA) is a mass spectrometer that uses a focused laser for microanalysis. It employs local ionization by a pulsed laser and subsequent mass analysis of the generated ions.
== Patents == Although details have not surfaced, it appears that the University of Utah forced the 23 March 1989 Fleischmann and Pons announcement to establish priority over the discovery and its patents before the joint publication with Jones. The Massachusetts Institute of Technology (MIT) announced on 12 April 1989 that it had applied for its own patents based on theoretical work of one of its researchers, Peter L. Hagelstein, who had been sending papers to journals from 5 to 12 April. An MIT graduate student applied for a patent but was reportedly rejected by the USPTO in part by the citation of the "negative" MIT Plasma Fusion Center's cold fusion experiment of 1989. On 2 December 1993 the University of Utah licensed all its cold fusion patents to ENECO, a new company created to profit from cold fusion discoveries, and in March 1998 it said that it would no longer defend its patents. The U.S. Patent and Trademark Office (USPTO) now rejects patents claiming cold fusion. Esther Kepplinger, the deputy commissioner of patents in 2004, said that this was done using the same argument as with perpetual motion machines: that they do not work. Patent applications are required to show that the invention is "useful", and this utility is dependent on the invention's ability to function.
Sources: en.wikipedia.org
Cross-matching or crossmatching is a test performed before a blood transfusion as part of blood compatibility testing. Normally, this involves adding the recipient's blood plasma to a sample of the donor's red blood cells. If the blood is incompatible, the antibodies in the recipient's plasma will bind to antigens on the donor red blood cells. This antibody-antigen reaction can be detected through visible clumping or destruction of the red blood cells, or by reaction with anti-human globulin. Along with blood typing of the donor and recipient and screening for unexpected blood group antibodies, cross-matching is one of a series of steps in pre-transfusion testing. In some circumstances, an electronic cross-match can be performed by comparing records of the recipient's ABO and Rh blood type against that of the donor sample. In emergencies, blood may be issued before cross-matching is complete. Cross-matching is also used to determine compatibility between a donor and recipient in solid organ transplantation including heart/lung transplation.
== F == Favorskii reaction Favorskii rearrangement Favorskii–Babayan synthesis Fehling test Feist–Benary synthesis Fenton reaction Ferrario–Ackermann reaction Ferrier carbocyclization Ferrier rearrangement Fétizon oxidation Fiesselmann thiophene synthesis Finkelstein reaction Fischer indole synthesis Fischer oxazole synthesis Fischer peptide synthesis Fischer phenylhydrazine and oxazone reaction Fischer glycosidation Fischer–Hepp rearrangement Fischer–Speier esterification Fischer Tropsch synthesis Fleming–Tamao oxidation Flood reaction Folin–Ciocalteu reagent Formox process Forster reaction Forster–Decker method Fowler process Franchimont reaction Frankland synthesis Frankland–Duppa reaction Fráter–Seebach alkylation Free radical halogenation Freund reaction Friedel–Crafts acylation Friedel–Crafts alkylation Friedländer synthesis Fries rearrangement Fritsch–Buttenberg–Wiechell rearrangement Fujimoto–Belleau reaction Fujiwara–Moritani reaction Fukuyama coupling Fukuyama indole synthesis Fukuyama reduction
== External links == GeneReviews/NCBI/NIH/UW entry on Ehlers-Danlos Syndrome, Hypermobility Type This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
Suppliers normally quote a percentage of total chromatographic peak area, most often from reversed-phase HPLC. That figure says nothing about what the remaining percentage contains, and it depends on the detection wavelength used. A mass spectrometry result is a separate and stronger check on identity.
The methionine residue at the start of the chain is vulnerable to oxidation, producing a sulfoxide variant. Amide bonds can also hydrolyze, though more slowly under neutral conditions. Cold storage, oxygen exclusion and minimization of freeze-thaw cycles slow both processes but do not stop them.
A purity number on a certificate does not establish that a powder is the same product as a registered nasal medicine. Counter-ion content, residual solvents and peptide-related impurities may differ between the two. Independent verification is the only way to narrow that gap.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.